Research programme: muscarinic antagonist/beta-2 agonist therapeutics - Almirall S.A.

Drug Profile

Research programme: muscarinic antagonist/beta-2 agonist therapeutics - Almirall S.A.

Alternative Names: LAS-194871; MABA programme - Almirall S.A.

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall S.A.
  • Class Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Spain (Inhalation, Powder)
  • 03 Nov 2014 AstraZeneca and Almirall complete transaction to transfer rights to Almirall's respiratory franchise, including LAS 194871, to AstraZeneca ,
  • 30 Sep 2013 Preclinical development is ongoing in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top